- Home
- ACRV vs FLL Comparison
ACRV vs FLL Comparison
Compare ACRV & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- FLL
- Stock Information
- Founded
- ACRV 2018
- FLL 1987
- Country
- ACRV United States
- FLL United States
- Employees
- ACRV N/A
- FLL 1822
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- FLL Hotels/Resorts
- Sector
- ACRV Health Care
- FLL Consumer Discretionary
- Exchange
- ACRV Nasdaq
- FLL Nasdaq
- Market Cap
- ACRV 189.0M
- FLL 184.6M
- IPO Year
- ACRV 2022
- FLL 1993
- Fundamental
- Price
- ACRV $5.54
- FLL $5.33
- Analyst Decision
- ACRV Strong Buy
- FLL Strong Buy
- Analyst Count
- ACRV 6
- FLL 4
- Target Price
- ACRV $22.40
- FLL $6.50
- AVG Volume (30 Days)
- ACRV 69.3K
- FLL 156.7K
- Earning Date
- ACRV 03-27-2025
- FLL 03-06-2025
- Dividend Yield
- ACRV N/A
- FLL N/A
- EPS Growth
- ACRV N/A
- FLL N/A
- EPS
- ACRV N/A
- FLL N/A
- Revenue
- ACRV N/A
- FLL $279,132,000.00
- Revenue This Year
- ACRV N/A
- FLL $23.82
- Revenue Next Year
- ACRV N/A
- FLL $11.07
- P/E Ratio
- ACRV N/A
- FLL N/A
- Revenue Growth
- ACRV N/A
- FLL 28.57
- 52 Week Low
- ACRV $3.83
- FLL $3.77
- 52 Week High
- ACRV $11.90
- FLL $5.94
- Technical
- Relative Strength Index (RSI)
- ACRV 47.59
- FLL 60.18
- Support Level
- ACRV $5.00
- FLL $5.10
- Resistance Level
- ACRV $6.08
- FLL $5.56
- Average True Range (ATR)
- ACRV 0.64
- FLL 0.19
- MACD
- ACRV 0.01
- FLL -0.02
- Stochastic Oscillator
- ACRV 25.68
- FLL 58.18
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.